Abstract:Objective To compare the immune effects of Coxsackievirus B3 (CVB3) capsid protein VP1 expressed bacterially, recombinant adenovirus rAd/VP1 and recombinant plasmid pcDNA3/VP1which express VP1 protein in mice. Methods After expressed in prokaryotic cells, VP1 protein was purified. Recombinant adenovirus rAd/VP1 and recombinant plasmid pcDNA3/VP1 were amplified and extracted. Six to 8-week-old, male BALB/c mice were divided into four groups randomly. Each group contained 18 mice. The mice of pcDNA3/VP1 group or VP1 protein group were immunized intramuscularly with three injections at three weeks apart, of recombinant plasmid pcDNA3/VP1 at a dose of 100 μg/mouse or recombinant protein VP1 at a dose of 50 μg/mouse. The mice of rAd/VP1 group were immunized intramuscularly twice at two weeks interval with rAd/VP1 at a dose of 1.2 × 107 PFU. The control group was mock-immunized with 100 μl of PBS intramuscularly. Mice were bled from the retroorbital sinus plexus every two weeks after each immunization. ELISA and micro-neutralization test were used to detect levels of CVB3-specific IgG antibody and neutralizing antibody titers in the sera of immunized mice. Three weeks after the last immunization, the cytotoxic T lymphocyte(CTL) killing activity of spleen lymphocytes was detected with CCK-8 assay. Subsequently, virus titers in the sera of immunized mice were determined by the 50% cell culture infective dose( CCID50 ) assay on HeLa cell monolayers and percentage of animals surviving were observed after lethal CVB3 attack over a period of 21 days. Results The titers of specific IgG antibody and neutralizing antibody in sera of VP1 protein immunized mice were higher than other groups( P ＜0.05 ). While CTL killing activity of spleen lymphocytes of VP1 protein immunized mice was lower than mice in rAd/VP1 group( P ＜0. 05). Virus titers in sera of VP1 protein immunized mice were lower than the mice in pcDNA3/VP1 or rAd/VP1 groups ( P ＜ 0.05 ), while survival rate was significantly higher than these two groups ( P ＜ 0.05 ).Conclusion VP1 protein induced higher level of humoral immune response and acquired obvious immune protection effects in mice. The immunizing potency of VP1 protein vaccine surpassed plasmid pcDNA3/VP1or recombinant adenovirus rAd/VP1. It appeared to be a promising candidate among the three different vaccines.

Construction of the Recombinant Adenovirus Expressing the CVB3 VP1 Protein and Study on Its Immunological Effects in Mice

Construction of the Recombinant Adenovirus Expressing the CVB3 Svp1-C3d3 Protein and Study on Its Immunological Effects in Mice

Comparison of the Immune Effects of Coxsackievirus B3 VP1 Protein, Rad/vp1 and Pcdna3/vp1 in Mice

Enhancement of Mouse Immune Response by Recombinant Adenovirus Co-Expressing VP1-2A of Foot-and-mouth Disease Virus and Porcine IFN-α

Expression of CVB3 VP1 Protein in Prokaryotic System and Study on Its Immune Effects

The Immunological Effect of Ad/MDC-VP1 Combined with DNA Vaccine Against Coxsackievirus Infection

Construction of Recombinant Adenovirus Co-expressing VP1-2A of Foot and Mouth Disease Virus and Porcine IL-2 and Its Immune Effects

Comparative immunogenicity of subunit vaccine expressing CVB3 VP1 and targeted gene vaccine in mice

[The Effects of Inoculation Route and Adjuvant Type on the Immunizing Potency of CVB3 VP1 Protein].

[Protective immunoresponse to CVB3 induced by gene immunization with pcDNA3-VP1].

[Study on Combined Immunization of Rad/mdc-Vp1 and Pcdna3/mdc-Vp1 Against Coxsackievirus B3 Challenge in Mice].

Construction of Targeting DNA Vaccine Pcdna3/mdc-Vp1 and Its Immunological Effect on Mice

Study on Immunological Effect Fusion DNA Vaccine Pcdna3/mdc-Vp1 on CVB3 in Mice

Construction and Immunogenicity of Recombinant Adenovirus Expressing the Capsid Precursor Polypeptide P1 and P12A Plus 3C Proteinase of Encephalomyocarditis Virus

The Construction of Recombinant Adenovirus Inserted with Modified Epstein-Barr Virus Latent Membrane Protein 1 and the Study of Its Immune Effect

Effect of mouse IFN-γ gene adjuvant on immunogenic enhancement of secreting coxsackievirus B3 VP1 DNA vaccine

Construction and immune efficacy of eukaryotic expression vectors of PPV VP2 gene with different antigen epitopes of PCV2 ORF2 gene

Exosome-based Delivery of VP1 Protein Conferred Enhanced Resistance of Mice to CVB3-induced Viral Myocarditis.

Construction and Identification of Recombinant Adenovirus Expression VP1 of Foot and Mouth Disease Virus

Influence of Foot and Mouth Disease Virus of Recombinant Adenovirus Expression VP1 on Specific Immune Responses in Mice

Effect of interleukin-2 and interleukin-15 gene as adjuvant on coxasckievirus B3 VP1 DNA vaccine